Gillette Rx Vaniqa Deal May Be Anecdote To Hairy Third Quarter - Stock Index
This article was originally published in The Rose Sheet
Executive Summary
Gillette's joint venture with Bristol-Myers Squibb to bring the Rx product Vaniqa (eflornithine 15%) to market may be a prescription for growth following the company's rocky third quarter performance on Wall Street. The stock moved up 3/4 to 36-1/2 on Oct. 4, the day of the announcement.